BERYL DRUGS LTD.

Beryl Drugs Ltd has announced the closure of its trading window for all Board Members, Promoters, and Designated/Specified Connected Persons. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The company will intimate the date of the Board Meeting for declaring these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct.

Sudhir Sethi, a main promoter of Beryl Drugs Ltd, has acquired 6,950 shares, representing 0.13% of the company's total voting capital. This acquisition increases his total shareholding to 511,119 shares. The transaction was conducted through market transactions. The filing is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Beryl Drugs Ltd has announced the relocation of its registered office from 133, Kanchan Bagh, Indore to 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore. This move, approved by the Board of Directors on June 16, 2026, is for administrative convenience and is effective from July 1, 2026. The company's Corporate Identification Number (CIN) remains unchanged as the shift is within the local limits of the same city.

Beryl Drugs Limited announced the shifting of its registered office within the local limits of Indore. The new address is 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore- 452016 (M.P.), moving from its previous location at 133, Kanchan Bagh, Indore- 452001. This decision was approved by the Board of Directors during their meeting held on June 16, 2026.

Sudhir Sethi, the main promoter of Beryl Drugs Ltd, has acquired 30 equity shares, representing 0.005% of the total share capital. This acquisition, made through market transactions, increases his total holding to 504,169 shares, or 9.915% of the company's total voting capital. The transaction occurred on June 10, 2026.

Sudhir Sethi, a promoter of Beryl Drugs Ltd, has acquired 3,482 shares, representing 0.06% of the company's total share capital. This acquisition increases his total shareholding to 504,139 shares, or 9.85% of the total diluted share capital. The transaction was conducted through market purchases. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sudhir Sethi, a promoter of Beryl Drugs Ltd, has acquired an additional 4,682 shares, representing 0.1% of the company's total voting capital. This acquisition increases his total holding to 9.85%. The transaction was conducted through open market purchases. The total diluted share capital of the company remains at 50,71,700 shares.

Beryl Drugs Ltd has announced that its Board of Directors will convene on June 16, 2026, to consider and approve a change in the company's registered office. The proposed new address is 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore- 452016 (M.P.), relocating within the local limits of Indore from its current office at 133, Kanchan Bagh, Indore-452001. The meeting is scheduled for 02:00 PM at the registered office.

Sudhir Sethi, the main promoter of Beryl Drugs Ltd, has acquired 1992 shares, representing 0.03% of the company's total voting capital. This acquisition was made through market transactions. Following this purchase, Sethi's total shareholding in Beryl Drugs increases to 4,95,975 shares, constituting 9.75% of the total equity share capital.

Beryl Drugs Limited announced its audited financial results for the quarter and year ended March 31, 2026, along with the Independent Auditor's Report. The auditors highlighted a potential unrecorded liability for professional tax due to non-registration. Revenue from operations for FY26 was adversely impacted by a stop manufacturing order for its Blow Fill Seal (BFS) section, effective from February 2025 until its revocation on November 28, 2025. The company also adopted Ind AS 116 - Leases from April 1, 2024, resulting in a ₹30.03 Lakh adjustment to the opening balance of Retained Earnings.